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REPORT ON THE APPROXIMATION OF THE LAWS · 
RELATING '1'0 PROPRIETARY MEDICIN.AL PRODucrs 
I 
1. Th~ purpose of this report is to present 'the Commission's proposals and 
gUidelines in the field of proprietarY medicinal products in an overa:lJ,. 
.frameWork. The two main lines of action of the Corr,mLinit>' work are to 
faciLitate access to He market in ord~r to create a Large opeh market and 
-to im~rove its opera.tjon in:~ol'der t() create a- traAspar-ent and orderly market. 
-·'·I ~-·:A -large:-open market 
1. The results achieved 
2. Four Council Directives and one Council Decision, with the aim of 
abolishing barriers to the free movement of medicinal products, have ~ 
adopted. In abolishing these barriers, public health safeguards have been 
developed on two levels: that of the conception of the product and that 
of its manufacture. 
3. The first safeguard for the proper conception of a medicinal product 
consistS in the tests to be carried 9ut and the principles to be followed 
during these trials. 
The second safeguard is the ~doption of a system of prior authorization, 
this being subject to three ·fundamental conditions: the quality, harmless~ 
ness and therapeutic effect of the medicinal product. 
' ' 4. '!he safeguards relating to goo,d manufacture are based firstly on a 
manufacturing authorization issued in the light of conditions concerning 
,, 
premises, plant and staff, then on the compulsory presence of a qualified 
person in charge of manufacture and control -t;ests and, lastly,. on 
inspections carried out in manufacturing establishments. 
5~ Now .that these safeguards have been developed, it has been po~sible to 
do aw~y with systematic checks upon imports fr·crr one Member Sta~e to another; 
irrespective of the place of production in the Co~munity, medi~inal ~roducts 
are mar:ufactured and tested in a.ccordar~ce ~JiH the· same rules, and under the 
supervis/or. of persc,ns 1\ith equivalerr: qt:alifications. 
. ' 
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Nevertheless, marketing authOriz·ations have remained a national matter. 
In order to obviate divergent decisionS as far as possible, cooperation 
between competent authorites has taken place within a Committee for 
Proprietary Medicinal Products (hereinafter referred to as the CPMP) • 
6. Lastly, a Pharmaceutical Oonmittee has been set up in order to provide 
the Commission with appropriate advice in the field of proprietary 
medicinal products • 
2 • The inadequacies noted 
7. Generally speaking, the implementation of the Directives is satisfactory. 
All the Member States have introduced th~ system of prior authorization 
into their laws and only certain particular points of certain national 
laws have to be re~tified. The Commission is dealing with this, as 
provided for in Article 169 of the Treaty of Rome, in .relation to Belgium, 
Luxembourg and Italy. 
8. The requirements of a unified market have not always been fully taken into 
account in the Directives already adopted. Provisions which are satisfactory 
in a national market may be unsuitable or inadequate in a common market. 
Since persons as·well as goods circulate more and more on Community 
territory, it is important for public health that the same names should 
cover the same products, except where there are legitimate grounds to the 
contrary. 
\ 
Similarly, it is not enough for a competent authority to be aware of the 
marketing authorizations granted by the other Member States. It should 
also know what has been authorized and under what conditions. 
Finally, provisions which hamper trade between Member States must be kept 
to the minimum necessary for the protection of public health while provisions 
designed .to guarantee the homogeneousness of the experimental work in the 
various Member States must be prorroted and the alignment of decisions by 
the national authorities improved. 
9. There is a third category of inadequacy which results from the very provisions 
whirh have teer &~opted or Pt levst fro~ the little use ~hich has been made 
of thew, i.e. the CPMP procedure for the marketing cf proprietary ~e~icinal 
~~rcc!Licts. By the be-;;inning of Septen.ber 1980, i.e. over a period of nearly 
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four years, only eight applications had -been filed Under this procedure. 
' There has been, however, a ten:iency for the number of applications to 
increase during recent months which no doubt means that the circles concerned 
'have been better informed. 
Nevertheless, the pharmaceutical industry has reservations with regard to 
this procedure. Fundamentally,· it considers that the existing procedure is 
not at 'all appropriate to the, aim pursued and should, be replaced by a system 
I 
of mutual recognition. During an interim period, the present system could 
be modified in respect of two main points: the conditions for initiating the 
procedure are too restrictive; the applicant does not have any opportunity 
to ~ heard during the procedure. 
The O:msumers • ConSultative Committee, or rather one of its working parties, 
also considers the present procedure to be unsuitable; in its opinion, the 
cPMP does not have sufficient powers to be ab~e to work effectively. It is 
completely opposed to the recognition of authorizations and hopes for the 
gradual transformation of the CPMP into_ a European registration bureau. 
3. The improvements and additions proposed 
10. In view of the problems mentioned above and after extensive consultations 
with all the parties concerned, the Commission has adopted the following 
positions: 
- the provisions of Directives 65/65/EEC and 75/318/EEC must be brought up 
to date and supplemented in order to keep pace with the progress of science 
and to take better account of the requirements of a single market; 
- Chapter III of Direct~ve 75/319/EEC setting up the Committee fer Proprietary 
Medicinal P~oducts as provided for by Article 15(2) of the aforem~nticned 
Directive should be amended; under present market co~ditions and in the 
absence cf strons reascns based on public health, the setting up of a 
European bcdy for the iss~e and revocation of marketing auth6rizations does 
not appear to bt· advisable nor does the extension of the present system, 
whi eh is widely criticized and ther.efore has to be :_abandoned; _reco~nition of 
authorizations s~ems to be the simplest and most effective solution: 
a medicine manufactured a~d marketed in one Me~Ler State on the basis of 
harMonized provisions must, in principle, be .allowed on the mar-ket c:f any 
other Member State, disputed cases being submitted to the Committee for 
Proprietary Medicinal Products for an opinion; 
\ 
I / 1 
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.- the p~inciples to be followed when implementing the provisions of 
I , 
-Directive 75/318/EEC relating to the standards and protocols applicable 
t~ the testing of proprietary medicinal products should be determined 
in ord~r to promote the alignment of national ~ecisions; a Coun~il Re-
commendation appears to be the most appropriate means of keeping up with 
developments in sc-ience and technology and of taking into account the 
importance of protecting the patient and of pharmaceutical research. 
II. A transparent and orderly market 
11 •. 0wing to the approximat1on of national laws and conceptions, the 
marketing of medicinal prQducts no longer constitutes the barrier 
it did in the past. Other barriers consequently take on greater signi-
ficance with regard to the proper functioning of the market. It is 
therefore of crucial importance that the Community use the powers of 
supervision conferred on it by the Treaty and take the necessary har-
monization ,measures. 
12. The problems of medicine pric·es and reimbursement by the social security 
organizations are major barriers to free movement. The fjxing of prices. 
that are too low or the debarring of a medic1ne from reimbursement 
·constitute just as effective a. barrier as the refusal of a marketing. 
authorization. 
With regard to supervision, the thinking of the Commission and the 
case law of the Court of Justice, having regard to the implementation 
of Articles 30 - 36 of the Treaty, are clear. The Treaty basically 
leaves completely intact the power of-Member States to take appropriate 
-
measures with regard to-price formation; at.~he same time, however, 
Article 30 is violated when a price system does not permit either a 
producer or a Community importer to sell his product on the market· of 
that Member State at a remunerative pri.ce. Measures nave already been 
' 
taken and others are in preparation. 
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But it is equally· necessary to overcome the present dichotomy whereby 
' : 
medicines and social security, c~ns~mer protection and growth in 
consumption are brought into conflict by outline measures and guidelines 
intended to improve competition by way of prices. Greater competition 
could only facilitate the reform of the social security systems. 
It should be remembered in this context that the proposal for a Directive , 
sent to the Council on 2 June 1980 aims at establishing a harmonized 
system for the registration of parallel importers of prop~ietary medicinal 
products. In·particular, it proposes the prohibition of artificial 
' 
distinctions between products in the various Member States brought about 
either by therapeutically unwarranted adjustments in composition or by 
changes in the name of the product without Legitim~te reasons. 
The Commission will continue its efforts to establish a transparent and 
orderly market in which price could play the regulation role proper 
to it. 
2. Advertising 
13. Advertising is an important means of penetrating markets as well as 
being an instrument for the information of doctors and consumers. In a 
first approach t~e Commissi~n attempted to harmonize the differences 
between the relevant national Laws. It has proved impossible to find 
a common solution for the regulation of advertising: the preventive 
system (prior authorization), the repressive system (a porteriori 
penal~y cases of infringement) and the $ystem of self-regulation <volun-
tary code of conduct) seem to operate to the satisfaction of those 
acquainted with them. 
In a second approach the Commission attempted to bring into line the 
principles determining the coritent of advertising. But it quickly emerged 
that these common principles constituting, as it were, base-Level pro-
visions could not have any consequences from the point of view of the 
movement of products or competition, since each Member State would have 
remained free to add to these provisions. 
' ' 
_i \ 
I 
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The advantage of these lengthy discussions in the first instan~e was 
to stimulate some hard thinking on the part of the various circles 
' 
involved (authorities, industry, professiona~ groupings etc.) and 
subsequently to show that a proposal for a Dir~ctive could not, in view 
of this situation, constitute real progress. 
In addition, it should be remembered that there already is a proposal 
for a Directive on misleading and unfair advertising, which lays ~own 
the general basis for consumer protection. 
In these circumstances, the Commission does not think it advisable to 
make a specific proposal on proprietary medicinal pr~ducts. 
3. The future 
14. The economic, technical and financial problems, important. as they are, 
must·not·be·allowed to monopolize our attention. Research is the 
driving force of the pharmaceuticals industry and, a.ccording to a recent 
report, "biology and genetics are certain to play an increasingly im-
portant role in the manufacture of certain substances having a thera-
peutic action". 
With regard to research, the Commission sent to the Council on 22 January 
1980 a proposal for a five-year programme of indirect-action res~arch in 
the field of biomolecular engineering. On 4 August 1980, it sent to the 
Council a proposal recommending to the Member States the registration of 
work on deoxyribonucleic ac-id (DNA) recombination. 
It is time to think about the legal and regulatory consequences of the 
transposition of this research to the industrial stage, in particular 
its use in therapy. 
15. Finally we should foster an awareness outside the Community of the 
guarantee conferred by this gradual and flexible process of harmoni-
zation. It constitutes a kind of European.quality label which will 
henceforth be attached to all our products, and we should ensure that 
this has its effects at the level of international trade. 
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PROPOSAL FOR A a::>uNCIL DIRECriVE 
amending Directives 65/65/EEC, 75/318/EEC and 75/319/EEC on the 
approximation of provisions laid down by law, regulation or 
administrative action relating to proprietary medicinal products 
' ' The purpose of this proposal is twofold: 
- to bring up to date the Directives adopted in 1965 and 1975 in 
the field of proprietary medicinal products; 
- to amend the procedure of the Cormni ttee for Proprietary Medicinal 
Products and introduce the principle of the recognition of 
marketing authorizations. 
..... 
'. 
I 1 _,.. 
i. 
Explanatory memorandum 
I. General considerations 
1. This pro:p:>sal by the Corrnnission has a twofold aim: 
) ' 
. I \ .. _. ~' . ' 
- firstly, to amend the procedure of the Corrnnittee for Proprietary 
Medicinal Products ( CPMP) with a view to attaining the free movement of 
these products; 
- secondly, to amend and supplement the Directives alre?.dY adopted on the 
approximation of provisions laid down by ·law, regulation or administrative 
action relating to proprietary medicinal products with a view to bringing 
them up to date. 
2. As provided for in Article 15(2) of Directive 75/319/EEC, "in the light of 
experience the Corrnnission shall, not later than four years after the entry 
into force of this Directive, submit to the Council a pro:p:>sal containing 
appropriate measures leading towards the abolition of any remaining barriers 
to the free movement of proprietary medicinal products 11 • 
Experience has shown that the barriers to free ·movement connected with the 
system of national marketing·authorizations have not been substantially 
overcome by the Corrnni ttee for Proprietary Medicinal Products ( CP.MP) 
procedure set up under Chapter III of the above-mentioned Directive • 
. 
3. The four years during which the CPMP1 procedure has operated adequately 
demonstrate the industry's reservations towards it . 
. 
. The procedure itself, as laid down in Directive 75/319/EEC, is certainly 
under fire. It should therefore be improved, especially with regard to two 
main :p:>ints, according to the industry ~tself: the conditions for 
. ' 
initiating the procedure must be made less restrictive and the a~icants 
must have the op:p:>rtunity to be heard during the procedure. 
l ' 
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4. lbwever, in addition to the procedure, it seems that the system itself is 
under fire. 
The phannaceutical industry considers that the present procedures cannot be 
deemed in any way appropriate to the aim pursued. ·Mutual recognition, 
already adOpted in many fields, is the only system it can accept. 
en the other hand, the ~onsumers consider that recognitio;n, like the present 
procedures, cannot lead to a common European policy for proprietary 
n'ledicinal products. Only a system of Community authorizations issued by a 
European agency is compatible with this aim. 
The authorities of the Member States, which were consulted on various 
occasions within the Phannaceutical Conmi ttee ~ were unable to reach a 
·common position- although the majority were in favour- on the recognition 
of marketing authorizations in the fairly near future. 
5.- Bearing in mind these differing attitudes and tne \\Qrk of the Committee 
for Proprietary Medicinal Products, the Commission considers that merely 
improving the present procedure \\Quld not fundamentally alter the problems 
and \\Quld be contrary to the letter and the spirit of Article 15(2) of 
Directive 75/319/EEC. 
The Connnunity authorization soJ,.ution is, of course, very tempting as far as 
principles are concerned, but appears to be extreme in the present situation. 
The setting up of a European body with very highly qualified scientific 
experts, a large administrative staff and perhaps res_earch laboratories 
needed by those experts \\Quld be prohibitive from the point of view of cost, 
all the nore so since this European body \\Quld have to operate concurrent! y 
with the national bodies for an indefinite period. 
Even without co~idering the political, legal and material problems which 
\\Quld be involved in a solution of this kind, the financial burden of such 
a venture seems to' be enormous compared with that of the present situation 
and the results which may be expected of it. 
6. The Commission therefore proposes ,that recognition of marketing authorizations 
issued by the national authorities on the basis of harmonized provisions be 
introduced. A proprietary product manufactured and marketed in one State in 
accordance with the harmonized regulations must, with certain exceptions, 
be allowed on the markets of the other Member States. 
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In disputed cases, the CPMP shall be called upon to give an opinion. 
Such, in brief, is the economic aspect of the proposal for the gradual 
achievement of the free movement of proprietary medicinal products. 
The provisions intended to update and supplement the Directives already 
adopted will be dealt with one Article at a time in the · coimlentary. 
\ 
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II. Commentary on the·Article~ 
Article 1 
7. The purpose of this Article is to amend Council Directive 65/65/EEC. 
The chief amendment concerns the introduction of the data sheet (paragraphs 
2 and 3) which is a sort of photograph of the authorized proprietary 
medicinal product. In other words, this is a document which provides a 
synthesis of the product's qualities and defects such as they have been 
recognized by the competent authorities. 
This sheet should enable the competent authorities to keep track, in a 
summarized form, of what has been authorized. 
It should enable manufacturers to kno~ exactly what information they can 
impart in their communications to the general pUblic and the professional 
circles concerned. 
OWing :to their changing nature, the economic particulars referred to in 
paragraph 3.8 have not been made compulsory. Nevertheless, it would appear 
useful to concentrate, as far as possible in the same place, all particulars 
con~erning proprietary medicinal products whether medical, administrative 
or economic. 
, 8. The other amendments do not call for any particular comment except that 
concerning Artricle 13 .1. Regular mention of the international non-
proprietary name recommended by the World Health Organization after the 
special name seems to be absolutely necessary to ensure at least some 
transparency in the medicines 1 market. For doctors and pharmacists it is 
the essential means of recognizing the real identity of productS which 
appear under so many special names • This is, therefore; a fundamental 
provision from the point of view of health and competition. 
1 ' 
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Article 2 
9~. The purpose of this Article is to amend Directive 75/318/EEC. 
The essential aim of the amendments relating to Part l of the Annex to the 
Directive (physico-chemical, biological or microbiological tests) is to 
- ' ' 
clarify and define certain points. 
10. On the other hand, the principle cf the bioavailability and mutagenesis 
studies has been introduced as a result of progress in scientific knowledge-. 
The bioavailability study provides information on the rate at which and in , 
what proportions a medicine's active principle or fraction thereof reaches 
the site where its action should occur when the medicine is administered 
in a particular pharmaceutical form. 
Mutagenesis concerns. the changes in the gene~ic material of individuals or 
cells which are spontaneous or caused by chemical products or radiations 
and which result in the following generations differing abruptly from those 
which preceded them in a permanent and hereditary way. All present scientific 
knowledge in this field_ is based on the hypothesis that many chemical 
products posses_s much mutagenic properties and it is therefore necessary to 
identify and limit the-diffusion of these products in the human environment. 
Any new therapeutic substance which contains new excipients and new active 
principles and to which extensive exposure is forecast must be tested for 
mutagenicity. 
The tests involved and those for bioavailability will be conducted accordimg 
to the principles expounded in Oommission Recommendations. 
Article 3 
ll. This Article amends Chapter III of Directive 75/319/EEC relating to the 
Oonunittee for Proprietary Medicinal Products. 
The previous system, which made the CPMP, to which reference was made from 
the very beginning, the hub of marketing authorization, is replaced by that 
' ' 
of the ·recognition of the initial authorization which mainly concerns the 
manufacturer and the Member States to which he submits his application. 
The CPMP is simply informed and it steps in to give an opini9n only in 
exceptional cases where recognition might be disputed. 
I 
, I 
J ,- ', 
r '\, ,•-
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12 .·I The previous Article 8, which defined the role of the CPMP, is amended in 
respect of two :p:>ints; the a±m of the mutual recognition of authorizations 
is introduced and the CPMP ~ s fOle is explained: it examines any question 
concerning the quality, safety and efficacy of a specific medicinal product 
or of a group of medicinal products • 1 
13. The principle of recognition and the procedures for the application for 
recognition are laid down in Article 9. In order to make this application, 
the proprietary product in question needs only to have obtained a marketing 
authorization in another Member State. Under the previous system, not only 
was this initial authorization necessary to set the CPMP in motion but, in 
addition, a request had to be made for the product to be marketed in at . 
least five other Member States. 
14. The cases of referral to the Committee are laid down in the new Articles 
10, 11 and 12. 
- where .an authority does not recognize the authorization (Article 10-); 
- where national decisions clash (Article 11); 
- where, before taking a decision, an authority wishes . to have the opinion 
of the CPMP concerning a problem of Community interest (Article 12). 
15. Recognition is normally obtained within a fixed'perio9. of 120 days. This 
period is relatively1long, bearing in mind the considerable'work on the 
re-examination of old products at the expense of the authorities pursuant to 
Article 39(2) of Directive 75/319/EEC and bearing in mind the fresh tasks 
entrusted to the national authorities pursuant to the qew Article 13 and the 
:p:>ssibilities of shortening this period provided for in Article 15(2). 
16. Thus, as soon as the Directive (Article 4) enters into force, the period of 
120 days will be reduced to 60 in the case of the proprietary· medicinal 
products referred to in Article 13 ( 1) • These are proprietary products 
containing a new active substance, i.e. one which is the subject of an 
application for marketing authorization for the first time in the Member 
State concerned. This ~w procedure is thus intended for new pr:oducts 
rather than for old ones already. sold on the various markets. 
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Cbrnpliance with this shorter period is facilitated by the eXistence ·of 
assessment reports on the results of tests drawn up by at least one 
Member State; these reports constitute, so to speak, the statement of the 
reasons justifying the grant of the authorization. At first sight, it may 
seem paradoxical to reserve this rapid procedure \for new products which, 
by definition, are less well known than the old products. Nevertheless, 
the latter are the subject of national re-assessments (cf. Article 39 ( 2) 
of Directive 75/319/EEC) which take into consideration experimental data 
_and published particulars (cf. Article 4, item 8, 2nd subparagraph) that. 
are often difficult to assess. 
en the other hand, new products have been the subject of thorough 
experimentation in accordance with common principles which comply with the 
state of the art in science and which are expounded in explanatory notes 
concerning the tests concerned with the marketing of proprietary medicinal 
products. This experimental work has been carefully assessed by the 
competent authorities of at least one Member ·state which have provided 
all the justifications for their decision. Better knowl~e of the medicine 
in question will be obtained not so much from a fresh administrative 
examination of the same data a..c:; from monitoring the product after it has 
been marketed. 
Furthermore, the assessment· report shall be supplemented, where necessary, 
by particulars stemming from drug-monitoring systems, for example 
(Article 13( 3)), i.e. by information on the adverse reactions to medicinal 
products obtained after they have been marketed. 
17. Article 14 contains the rules of procedure which apply when a matter is 
referred to the CPMP. Cbmpared with the previous rules, there is a change 
of form, in so far as the rules which were previously dispersed over 
several Articles are gathered together here, and of substance. The person 
resppnsible for placing a product on the market may explain himself 
I . 
verbally or in· writing before the CPMP, a prodedure which was strongly 
requested by the industry. 
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THE COUNCIL dF THE EUROPEAN COMMUNITIES, 
Having regard to the T~eaty establishing the European Economic Community, 
and .in particular Article 100 thereof; 
Having regard to the proposal, from the Commission; 
Having regard to the Opinion of the European Parliament; 
Having regard to the Opinion of the Economic and Social Committee; 
Whereas th~ Directives on the approximation of the Laws relating ~o 
proprietary medicinal products must be adapted to scientific progress and 
take account of the experience obtained since their entry into force; 
Whereas Council Directive 75!319/EEt on the approximation of provisions 
laid down by law, regulation or administrative action relating to 
proprietary medicinal products (1) provides in Article 15(2) that "the 
'.Commission shall submit to the Council a proposal containing appropriate 
measures leading towards the abolition of any remaining barriers to the 
free movement .of proprietary medicinal products", not later t,han four 
years after the entry into force of the above-mentioned Directive; 
Whereas it is necessary from the point of view of public health and the 
free movement ~f ~roducts that the competent authorities, manufacturers and 
consumers may have readily at their disposal all useful information on 
autho~ized proprietary products, in particular by means of data sheets and 
appropriate labelling; 
Whereas it is necessary to specify certain provisions relating to physico-
chemical, biological ·or microbiolog'ical tests on proprietary medicinal 
products and to introduce the principle of bioavai labi l ity' and ·mutagenesis 
tests in order to safeguard pub~ic health; 
. (1) OJ L 147, 9.6.1975 
, I 
/ ' 
' ' ' ,, 
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Whereas the approximation of Laws brought about in this connection must 
enable a proprietary product, manufactured and marketed in one Member State 
on the basis of Harmonized provisions, to be allowed on the market of any 
other Member State by virtue of the recognition of the initial authorization, 
save in exceptional cases subject .to the opinion of the. Committee for 
Proprietary Medicinal· Produc~s, 
HAS ADOPTED THIS DIRECTIVE: 
.. 
(2~ 
'' ' l, ~ r '' • \ • 
. '( I 
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ARTICLE 1 
Council Directive 65/65/EEC. on the approximation of provisions laid down by 
law, regulation or administrative action relating to proprietary medicinal 
products (1) shall be amended as follows: 
( 1) Article 4 shall be amended thus: 
(a) Point 6: the words "if less than three years" shall be deleted. 
(b) Point .8(a) of the English version: the words "published references" 
shall be replaced by ''published data". 
(2) '!be following Article 4a shall be inserted after Article 4: 
"'!be application referred to .in Article 4 shall also be accompanied by 
a data sheet which shall contain the following information: 
1. Name of the proprietary product; 
2. International non-proprietary name recorrmended by the WOrld Health 
~anization, where such name exists, of each active ~inciple; 
or failing this, the generic name or chemical description;. 
3. Pharmaceutical form; 
4 ~ Pharmacological properties and, insofar as this information is 
' useful for therapeutic purposes, pharmacokinetic particulars; 
5. Clinica+ particulars: 
5.1 therapeutic indications 
5.2 contra-indications 
5 ._3 undesirable effects (frequency and gravity) 
5 • 4 special precautions for use 
5 • 5 use during pregnancy and lactation 
5.6 interaction with other medicaments and other interactions· 
5.7 posology and method of administration 
5 • 8 overdose (symptoms, emergency procedures , antidotes ) 
5 . 9 special warn~ngs. / 
(1) OJ 22, 9.2.j965 
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6. Pharmaceutical particulars: 
6.1 qualitative and quantitative composition in active principles 
6.2 constituents of the excipient Which must be known in ord~ to 
permit correct administration of the medicinal product 
6.3 major incompa~ibilities 
6.4 shelf life 
6. 5 special precautions for storage 
6.6 contents of container 
6.7 name or style and permanent address or registered place of 
business of manufacturer". 
( 3) The following Article 4b shall be inserted after Article 4a: 
"The competent authorities of the Member States shall take all necessary 
_; 
I 
measures to ensure that the cdntents of the data sheet are in conformity 
with those accepted when the authorization is issued or subsequently. 
In addition, the data s~eet referr~ to in Article 4a shall be 
supplemented by the following information: 
7. Administrative particulars: 
7.1 marketing authorization number 
7.2 conditions of sale to the public 
7.3 date on which data sheet .was drawn up and date of its last revision. 
> 
Moreover, the data sheet may be supplemented by the following information: 
8. Economic particulars: 
8.1 selling price to the public of the various sizes of packs 
8.2 cost of daily treatment 
8. 3 situation in respect of health insurance." 
( 4) Article 5, paragraph 2 , shall be amended thus : 
"Authorization shall likewise be refused if the particulars and documents 
submitted in support of the application do not comply with Articles 4 
and 4a." 
, - I 
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( 5) The following Article 9a shall be inserted after Article 9: 
"After an authorization has been 'issued, the person resf)onsible for placing 
the product on the market must, in respect of the control method provided 
for in Article 4, point 7, take account of technical and scientific progress 
and introduce any changes that may be required to enable the proprietary 
medicinal product to be more reliably ch·ecked." 
( 6) Article 10 shall be amended thus: 
"An authorization shall be valid for five years and shall be renewed 
for fiv1e-year periods on application by the holder at least three months 
preceding expiry. 11 
(7) Article 11, paragraph 2, ~hall be amended thus: 
11 An authorization shall also be suspended or revoked where the particulars 
supporting the application as provided for in Articles 4 and 4a are found 
to be incorrect or have not been amended in accordance with Article 9a, 
or when the controls referred to in Article 8 of this Directive or in 
Article 27 of the Second Cbuncil Directive 75/319/EEC of 20 May 1975 on the 
approximation of provisions laid down by law, regulation or administrative 
action relating to proprietary medicinal products have not been carried out. 11 
(8) Article 13, points 1, 2 and 7, shall be amended thus: 
1 ~'-l. Name of the proprietary product which may be a brand name, or a corrnnon 
name together with a trade mark or name of the manufacturer, or a 
scientific name together with a trade mark or name of the m~ufacturer. 
WhErre the special name of a medicinal product containing onLy one 
ac1:ive principle is a brand name, this name must in all cases be followed 
by the international non-proprietary name, in Legible characters, 
recommended by·the World.Health Organization where such name exists." 
"2. A statement of the active principles expressed qualitatively and 
quantitatively per dosage unit or as a percentage, according to the 
pharmaceutical form, using the international non-proprietary names 
where such names exist. 11 
"7. E:xpiry date in plain language. 11 
.I 
'" 
• I 
'' I ' .; 
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ARTICLE 2 
The Annex to Council Directive 75!318/EEC on the approximation of the Laws 
of ~ember States relating to ana'Lytical, pharmaco-toxicological and clinical 
standards and protocols in respect of the testing of proprietary medicinal 
products1 shall be amended as follows: 
(1) In Part 1, C1, the' seventh paragraph s~all be reolaced by the following 
text: 
11 The routine tests to be carried out on each batch of starting materials 
must be stated in the application for marketing authorization, with proof 
that each batch of starting materials meets the quality requirements of 
the monograph of the pharmacopoeia coricerned. 11 
The eighth p~~agraph shall be supplemented thus: 
11They shall inform th~ responsible authorities whic~ pharmacopoeia is 
referred to. 11 
(2} In Part 1, C, the following paragraph 3 shall be inserted: 
11 3. Physico-chemic~l characteristics Liable to affect bio-availability 
The following items of information concerning active principles, 
I 
whether or not Listed in the pharmacopoeias, shall be provided if 
they relate to the bioavailability of the medicinal product: 
- crystalline form and solubility coefficients, 
- particle size, where necessary after pulverization, 
- state of hydration, 
- oil/water partition coefficient, 
the requirements of the first three indents not .being applicable 
to, substances used solely in solution:U 
(3) 1n Part 1, E, the following second paragraph shall be inserted: 
11A batch of a proprietary medicinal product is all the units of a 
" pharmaceutical form which are made from the same initial mass of material 
and have undergone a single series of mechanical operations or a single 
sterilization operation ... 
1
oJ L 147 of 9.6.1975 
•• :. ! • ,. ~ ' .._ 
' ,, 
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I (4) The first paragraph of Part 1, E, shall be supplemented by the following 
4th ~ubparagraph: · 
wFurthermore, solid pharmaceutical forms having to be administered by 
oral route shall, where necessary, be subjected to in vitro studies on the 
liberation and dissolution rate of the active- principle or principles •. 
Until standards are published by the European Pharmacopoeia, the. conditions 
of the experiment and the apparatus employed shall be precisely described." · 
(5) In Part 1; E 2, the second subparagraph shall be supplemented thus: · 
"Except in the case of appropriate justification, the. maximum acceptable 
deviations may not ·exceed 5%." 
(6) In Part 1, E 3, the third subparagraph shall be'replaced by the following, 
text: 
"An upper limit 'test shall be obligatory in respect of preserving agents 
and any other excipient constituent liable to affeet physiological 
. . 
functions; an upper and lower limit test shall be obligatory in respect 
of thE~ excipient if it is liiilile to affect the bioavailability of an 
activE~ 'substance." 
(7) In Part 1, E 5, the first subparagraoh shall be replaced by the following 
/ . 
text: 
"If general monographs on pharmaceutical forms appear in the European 
Pharmacopoeia or in the national pharmacopoeias of the Meffib,er States, -
~inished products must meet the requirements contained therein. If not, 
they shall be the subject of the de terminations below." 
' . 
I 
In addition, the subparagraphs referred to above shall be am~nded as 
follows: I 
"~j~~!~!~_2!:~2~~!!~~~: "10 ml" shall be replaced by "15 ml"." 
"Q!~~=~~L-~~~L-~!~·= colour and consistency; particle size of the 
acti v•= principles; weight and acceptable margin of variation; nature of 
container; microbiological control tests, if n~cessary." 
"~~~!~~.: colour; sedimentation rate; where settlement occurs, the 
· ease with which the -suspeilsion can be resumed." 
11 Su;e~~!!~!:!~~-~~-~~~~!~: colour; particle size of the active 'principles; 
weight and acceptable variations in unit weight; melting temperature or 
\ 
disintegration time, with the methods used to determine these." 
. ; 
... 
·-
(8) In Part ·2, Chapter I, the following titleD' shall be inserted between 
titles "D" and "E": 
"D I MUTAGENIC Par.ENTIAL 
The purpose of the study of mutagenic potential is to reveal the changes 
which a substance may cause in the genetic material of iridi vipuals or 
cells and which have the effect of making successors permanently and 
hereditarily different from their predecessors. This study is obligatory 
for any new substance. " 
(9) In Part 2, Chapter I, the title "E. CARCINOGENICITY" shall be 
I 
replaced by: "E. CARCINOOENIC Par.ENTIAL". 
In addition, the first subparagraph shall be amended as follows: 
"Experiments intended to reveal carcinogenic effects shall normally be 
required:". <The rest remains unchanged). 
Furthermore, a point 3 shall be inserted: 
"3. in respect of substances having given positive results in the mutagenic 
potential tests or in other short term carcinogenicity tests". 
(10) In Part 2, Chapter I, G, the following new subparagraph shall be inserted 
between the fourth and fifth subparagraphs: 
"For medicaments which must be subjected to a bioavailability assessment, 
the data must include changes in the results as a function of time and, more 
qene~ally, indicate the bioavailability of th~ product or of its metabolites. 
(11) In Part 3, Chapter II, the title "A. Pharmacolbgical Particulars 
(Clinical pharmacology)" shall be replaced by "A. Pharmacological Particulars 
(Clinical pharmacology and bioavailability) ·~. 
This same Chapter II, A, shall be supplemented by a paragraph 5, worded as 
follows: 
"5. The assessment of bioavciilability must be undertaken in all cases where 
it is essential in the interests of patients, e.g .. where the therapeutic 
safety margin is narrow or where the previous tests have revealed 
anomalies which may be related to variable absorpt-ion." 
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ARTICLE 3 
Directive 75/319/EEC on the app~oximation of provisions Laid down by Law, 
regulation or administrative action relating to proprietary medicinal 
products shall be amended as follows: 
The provisions of Chapter III shall be replaced by the following provisions: 
"Article 8 
l. In order to facilitate the adoption of a C?mmon position by the Member 
States regarding marketing authorizations ar.d to permit their mutual 
recognition, a Oommittee for Proprietary Medicinal Products, hereinafter 
referred to as 11 the Oommittee 11 , is hereby set up. The Oommittee shall 
consist of representatives of the Member States and of the Oommission. 
2. The responsibility of the Oommittee shall be to examine, at the request of· 
one of its members, any question concerning the quality, safety and 
efficacy of proprietary medicinal products and, in particular, in accordance 
with Articles ~ to 14, questions .concerning the application of Articles 5 
and ll of Directive 65/65/EEC. 
3. The Q)mmi ttee shall draw up its own Rules of Procedure. 
Article 9 
l. A holder of a marketing authorization issued in a Member State in accordance 
with the provisions of the Directives relating to proprietary medicinal 
• 
products may request recognition of such authorization when he files an 
application for authorization in one or more Member States, in accordance 
with Article 4 of Directive 65!65/EEC. 
2. He shall inform the cOmmittee of .this application, mentioning the Member 
States with which he has filed it, and also forward to the Oommittee a 
copy of the marketing authorization or authorizations already issued. 
3. The Cbmmi ttee shall forward this information to the Member States • 
4. The Member State(s) concerned shall grant recognition by issuing ~n 
authorization valid on their market within 120 days after the notification 
refe~red to above or withiri 60 days thereafter in the case of a proprietary 
medicinal product of 'the kind referred to in Article 13(1), without 
prejudice to the provisions set out below. 
r 
.'( ' ' .\ 
. ~ ' .. 
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Article 10 
1. Where a Member State considers that it is unable to recognize a marketing 
authorization, it shall forward to the Committee and to the peFson 
responsible for placing the proprietary medicinal product on the,market 
its reasoned object~on on the basis of Article 5 of Directive 65/65/EEC, 
.. 
within the time limits stipulated in Article 9(4). 
2~ Upon the expiry of this period, the matter s~all be referred to the. 
Committee and the procedure referred to in Article 14 shall be applied. 
3. On receipt of the reasoned objection mentioned in paragraph 1, the person 
responsible fo~ placing the proprietary medicinal product on the market 
shall immediately submit to the Committee one copy of the particulars and 
documents enumerated in Article 4(2) of Directive 65!65/EEC. 
Article 11 
' • I' ~ ~:~ ' 
If several applications submitted in accordance with Article 4 of Directive 
65/65/EEC have been made for a particular proprietary medicinal product, and 
one or more Member States have granted an authorization while one or more of 
the other Member States haVe refused it, a member of the Cbnuni ttee may request 
the Committee to apply the procedure mentioned in Article 14. 
The same shall apply where one or more Member States have suspended or revoked 
the marketing authorization while one or more other Member States have not 
done so. 
Article 12 
The competent ~uthorities of Member States may, in specific cases where the 
interests of the Cormrunity are involved, request the Committee to apply the 
procedure provided for in Article 14, before they reach a decision on an 
application for a marketing authorization, its-suspension or revocation and, 
in particular, when they intend to reject an application which concerns a new 
. I 
proprietary product such as that which is referred to in Article 13 ( 1) and 
which has already been authorized in another Member State. 
. I 
, I 
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Article 13 
1. In order to facilitate any discussions by the Corrmit.tee, the competent 
authorities shall draw up a report to assess the results of the 
analytical and toxico-pharmacological tests and clinical trials of any 
proprietary product containing a new active sUbstance which is the 
· subject of an application for a marketing authorization in the Member 
State concerned for the first time or of any other proprietary product 
they may choose. 
2. As soon as 'the notification referred to ;in Article 9(3) is received, 
the competent authorities shall forthwith forward to the other Member 
States and to the Corrmi ttee any assessment report relating to the s,ame 
I 
proprietary product or to a proprietary product containing the same 
active substan~e. This shall also apply as soon as reference is made 
to the Corrmi ttee pursuant to Articles 11 and 12. 
3. If necessary, the assessment report shall be updated, namely by 
information stemming from the drug-monitoring systems. 
Article 14 
1. When reference is made to the procedure described i:n .this Article, the 
Corrmittee shall consider the matter and express a reasoned opinion 
within 60 days of the date on which the matter was referred to it. 
In the cases referred to in Article 10, the person responsible for 
placing the product on the market may, at-his request, explain himself 
verbally or in writing before the Corrmittee expresses its opinion. 
He may also obtain the suspension of the abovementioned time limit. 
2. The Committee's 'opinion shall concern the compliance of the proprietary 
I 
'-
medicinal product in question with the conditions laid down in Article 5 .' 
or Article 11 of Directive 65/65/EEC. 
The Committee shall' _forthwith inform the lvlember State{s) concerned and the 
person responsible for placing the product on the market of its opinion 
or of those of its members in the case of differences of opinion. 
3. The Merllber States) concerned shall decide on the actio~ to be taken 
following the Conrni ttee 1 s opinion within 30 days of receiving the 
information referred to in paragraph 2. They shall forthwith inform the 
Committee of their decision(~). • 
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Article 15 
1. The Corrunission shall report to the Council biennially on the operation 
of the procedure 1 aid down in this Chapter and its effects on the 
developnent of intra-Community trade. 
on the basis of Article 100 of the Treaty, 
2. In the light of experience, the Corrunission shal]/propose by 1 January. 1988 
at the latest the reduction of the periods referred to in Article 10 
and, where necessary, any additional measure aimed at facilitating the 
mutual recognition of marketing authorizations. 
3. The Council shall decide on the Corrunission 's proposal by 1 January 1989 
at the latest." 
ARTICLE 4 
Member States shall bring into force the laws, regulations and administrative 
provisions needed in order to comply with this Directive by 1 January 1983 
at the latest and shall forthwith inform the Commission thereof. 
Member States shall communicate to the Corrunission the. text of the main 
provisions of national law which they adopt in the field covered by this 
Directive. 
ARTICLE 5 
This Directive is addressed to the Member States. 
Done at Brussels, ••••. 
For the CounciL 
The President 
PROPOSAL fOR A COUNCIL RECOMMENDATION 
concerning tests relating to the placing on the market 
of proprietary medicinal products 
' J 
SUMMARY 
' ' . 
,. ' !> 
;r 
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PROPOSAL FOR A COUNCIL RECOMMENDATION 
toncerning tests relating to the placing on the market 
of proprietary medicinal products 
,. I 
The Co~mission oroposes that Member States should ensure tbat tes~ relating 
to the placing on the market of Rroprietary medicinal products are conducted 
and presented in accordance-with the principles and methods set out in the 
notes for guidance pursuant to Directive 75/318/EEC on standards and proto-
cols in respect of the testing of proprietary medicinal products. 
. 
These notes deal with the following aspects of safety and efficacy of drugs: 
- single dose toxicity, 
- repeated dose toxicity, 
- reproduction studies, 
carcinogenicity, 
pharmacokinetics and metabolism in animals, safety studies, 
- fixed combination products. 
... ,. ·:· 11 ..... ~:·~I ~ ·_,;.'._I '• '·~ ,, ~ !I,", . 
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EXPLA~ATORY MEMORANDUM 
1. For four y~ars the Member States ~ave been aut~rizing the placing on 
the market of proprietary medicinal products by applying at first three; 
and now four, Council Directives *. 
Direct·ive 75/318/EEC relates in particular to tests designed to verify the 
safety, efficacy and quality of the drug before it is placed on the market. 
The Annex to this Directive describes in very general te~m~ the various 
categories of tests to be carried out in the analytical, pharmaco-toxi- . 
cological and clinical fields and gives some·indication of how documents 
and results are to be presented. 
2. Experience.has shown that differences of opinion not infrequently arise 
between nation~l authorities as regards the indications, contra-indications, 
etc. for a given drug and even as to the desirability of granting or 
refusing ~uthorization to place it on the market. 
The Commission has found on the basis of .this experience that the degree 
of harmonization achieved by the.existing Directives would not be 
sufficient to create the conditions necessary for the free movement of 
proprietary medicinal products unless it were matched by greater co-
operation between the competent national bodies. 
3. The Committee for Proprietary Medicinal Products **, which was set up in 
order to facilitate the adoption of a common approach by the ~ember 
States on the question of marketing authorizations and is composed of· 
' representativ's of the national a~thorities and the Commission, undertook 
to·review the present national and international requirements and to seek 
joint solutions that take account of current scientific and technical 
knowledge. The Commission has from the outset s4pported this scheme, 
which is likely to bring about a significant alignment .of the points 
' 
• of view of the national authorities. To this end the Committee has set up, 
* - Directive-65/65/EEC ~f 26 January 1965 
Directive 75/318/EEC of 20 May 1975 
- Directive 75/319/EEC of 20 May 1975 
- Directive 78/25/EEC of 12 December 1977 
** Directive 75/319/EEC, Chapter Ill 
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under Articl~ 13 of its rules of procedure, two groups of scientific 
experts designated by the Member States to draw up, in accordance with 
certain priorities, notes for guidance relating to the free movement of 
proprietary medicinal products within the Community. 
' 
4. The drafting and consultation procedure for these notes for guidance is 
designed to ensure that they will be valid and accepted both by the 
competent authorities and by the manufacturers concerned. The drafts 
of the two groups of scientific experts on "safety" and "efficacy" have 
been prepared in conjunction with specialists in the field concerned. 
The drafts approved by the Committee for Proprietary Medicinal Products 
were sent for consultation to the national authorities and to associations 
representing the pharmaceutical industry. 
The drafts were then re-examined by the experts in the Light of the 
comments received and a final draft has been prepared which .the Committee 
has unanimously approved. 
5. In substance, these notes are based Largely on current requirements or on 
requirements which are in the process of being drawn up at both national 
and international level. In the wider context of the toxicity of new 
chemical substances, similar texts will be recommended by the Commission 
in the sixth amendment to the 1967 Directive on dangerous substances • 
. 6. The main advantage qf these notes for applicants for marketing authoriza-
tions is to inform them in advance of "the requirements· of national 
authorities so that they .avoid additional delays in the completion of 
their dossiers. For trade within the Community and, in the long run, 
with non-member countries as well, these notes will spare applicants 
the need to repeat similar tests. Up to now experimental models have been 
defined differently in different countries. 
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These additional delays and duplications exist at the m~ment and have 
a detrimenta~ effect on the cost of new medicines. From an ethical·· 
point of view, it is des~rable in particular to avoid the repetition 
of clinical tests on man and the pointless proliferation of animal 
experiments. 
7. This first set of notes for guidance is concerned more particularly 
with all aspects of the safety of medicines, other than mutagenicity. 
The Commission intends to propose the introduction of that discipline 
into the categories of tests Listed in Directive 75/318/EEC. The notes 
for guidance concerned with safety will be reviewed from time to time 
to ensure that they are continually adapted to scientific and technical 
progress. 
8. This set also contains a note.on the efficacy of proprietary medicinal 
products containing a fixed combination of active principles. 
~ More specific notes dealing with clinical tests on medicinal products 
belonging to certain therapeutic categories are being elaborated. 
9. These scientific texts, which are guidelines rather than binding require-
ments, mtist be interpreted in a flexible manner and shall be revised 
periodically. The Recommendation is therefore the most appropriate· 
instrument. 
As these guidelines are of major importance for patient protection and 
for pharmaceutical research, the Commission proposes to the Council to 
adopt such a Recommendation, after consultation of the European Parliament 
and the Economic and Social Committee. 
11 
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THE COUNCIL OF THE EUROPEAN COMMUNITIES~ 
·Having regard to the Treaty establishing the European Economic Community, 
Having regard to the proposal from the Commission, 
Having regard to the Opinion of the European Parliament, 
Having regard to the Opinion of the E~onomic and Social Committee, 
'\ 
. I . *) 1. Whereas Council Directive 65/65/EEC of 26 January 1965 led to the approxi-
mation of provisions laid down by law, regulation or administrative action , 
r~lati~g to proprietary medicinal products in the Member States; 1 
whereas Directiv~75/318/EEC and 75/319/EEC of 20 May 1975**6ontinued 
this approximation and developed the principles set out in the original 
Directive; 
2. Whereas in particular Council Directive 75/318/EEC lays down a general 
framework for the testing of proprietary medicinal products; lists the 
va~ious types of tests to be conducted and defines certain principles 
to be followed in the examination of applications for authorization to 
place a proprietary medicinal product on the market; 
3. Whereas experience ~as shown that the conduct and content of these tests 
should be defined more precisely so as to make possible an.identical 
interpretation of the Community Directives when such tests are carried 
out and when applications are examined by national authorities; 
4. Whereas Notes for Guidance are therefore necessary in ordE~r to prevent 
differences of interpretation ·in the implementation of thE! standards and 
pro~edures listed in Directive 75/318/EEC and will help to promote the 
free movement of proprietary medicinal products; 
* ** OJ EC N° 22, 9~2.1965 
OJ EC N° L 147, 9.6.1975 
' ' } 
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· 5. Whereas tests designed to evaluate the quality, safety and efficacy of 
proprietary medicinal products must be constantly adapted to take account 
of the latest scientific and technical knowledge without, however,.giving 
rise either to a waste of resources or to the use of laboratory animals 
more than necessary; 
6. Where~s it is therefore highl~ desirable that the Notes for GUidance be 
periodically revised to take account of the state of the art and that new 
Notes for Guidance be drawn up as and when required, in agreement with 
the national authorities; 
7. Whereas such progress-in harmonization, essential at Community Level, 
will also promote international recognition of tests on medicinal products 
conducted in accordance with these Notes and will therefore tend to 
.render unnecessary the repetition of tests on products intended for export 
to non-Member States; 
8. Whereas the Pharmaceutical Committee and the Committe~ for Proprietary 
Medicinal Products have been consulted on the measures contained in this 
recommendation, 
HEREBY RECOMMENDS THE MEMBER STATES TO: 
1. ensure that, in the conduct of tests .and in the presentation of results, 
applicants for authorization to place proprietary medicinal products on 
the market comply with the principles and adhere to the methodology set 
out in the Notes for Guidance annexed hereto; 
2. examine and evaluate, in accordance with the Notes for Guidance, all 
applications for marketing authorization; 
3. apply these Notes for Guidance progressively and not Later than three 
years after notification of this recommendation. 
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ANNEX I: SINGLE DOSE TOXICITY 
-------
Note for Guidance concerning the application of the Annex of Directive 
75/318/EEC, 2nd part, Chapter I,. B 1, with a vie.w to the granting of. ·a 
marketing authorization for a new drug. 
1. INTRODUCTION 
'' I 
These guidelines deal with the qualitative and quantitative study of toxi~ 
phenomena and their occurrence r~lated to time after a single administration 
of the substance Cor combination of substances). 
These studies may give·some indication of the Likely effects of acute 
overdosage in man and may be useful for the design of repeated dose 
toxicity studies and reproduction studies on the relevant animal species. 
{ 
The single dose toxicity tests should be conducted in such a way that 
signs of acute toxicity are revealed ~nd the mode of death determined. 
In suitable species a quantitative evaluation of the lethal dose can be 
made but a high level of precision is not required. 
2. PRODUCT SPECIFICATION 
2.1 Drug Substance 
The active substance should have the same pattern of impurities as the 
product to be marketed, when possible. Should the final dosage fo~m be 
shown to have impurities significantly different either in quantity or 
quality from those in the test batch then further steps should be 
taken to ascertain their possible toxicity. Consideration should be 
given to the physical characteristics of the drug substances in relation 
to the route of administration, e.g. the particle size of a compound 
given orally. 
2.2 Fintshed Product 
When large animals are used in the acute toxicity study, it may be 
possible to conduct a study with the pharmaceutical formulation in-
tended to be marketed, and this is desirable. 
2.3 Excipients 
Where a new excipient is used for the first time it·should be evaluated 
BS a ne~ active substance. 
' 2.4 Products containing a Combination of Active Substances 
In the case of combination of active substances it is necessary to 
make a study of each active substance separately and of the combina-
tion of active substances in the same proportions as in the proposed 
final product in order that any change or potential toxic effects are 
revealed. 
2.5 Degradation Products 
Where degradation products occur under conditions of storage conside-
ration should be given to their possible toxicity and this might be 
best evaluated initially by an acute toxicity study. 
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3. ANIMALS 
3.1 Single dose toxicity tests must be conducted on at least two mammalian 
species of known strair using equal numbers.of both sexes. Rodents such 
as the mouse, rat and hamster are suitable for the qualitative study 
of toxic signs and the quantitative determination of the lethal dose. 
In the case of other mammals toxic signs should be observed anq re-
corded in detail for each animal used. 
3.2 Whatever species or strain of animals are selected it .is esse~tial 
that the following information should be provided, age, sex, weight, 
origin and the time spent in the laboratory before test, whether or not 
the animals are classified as being iree of specific pathogens, whether 
or not the animals have been vacc1nated or submitted to any other 
procedure. Details of housing and environmental conditions should be 
given. Access to and the nature of the diet and the availability of 
water should be stated. All the above factors are known to affect the 
acute toxicity of substances. 
4. ADMINISTRATION 
4.1 Route of Administration 
In the case of rodents at least two routes should normally be used and 
when possible should include tnose routes proposed tor man and at least 
one s~ould ensure full access of unchanged drug into the circulation. 
If the proposed route of administration to man is intravenous then 
use of this route alone in animal testing is acceptable. 
4.2 Conditions of Administration 
Details of administration of the product should be provided and include 
particulars of the vehicle or adjuvants used, method of preparing the 
suspension in the case of insoluble products, concentration of the 
solution used and the volume administered. The route and the method 
of administration should be clearly given. If the intravenous route 
is used the rate of infusion (ml/min.) and the pH and temperature of 
the solution administered should be provided. 
If it is n~cessary·to use more than one inj~ction site for parenteral 
administration this should be stated. 
4.3 Dose levels 
In rodents the number of dose levels used should be such as to enable 
the spectrum of acute toxicity to be revealed and to enable the LD50 
value with its 95 % fiducial limits to be determined for each route 
and both sexes, if possible. 
In other mammals the number of dose levels should be such that the 
spectrum of toxicity should be revealed and an estimate of the 
lethal ity · obtained. 
T "' , I'' \ ,, 1• \ 
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5. OBSERVATIONS 
Animals should be observed at regular intervals and all signs of toxicity 
and the time of their first occurrence and their ·severity and duration 
recorded. The time and mode of any death should be documented. When large 
experimental animals are used any signs of toxicity should be presented 
separately for each animal. 
' . Observation should usually be for 14 days, but should continue·so long as 
signs of. toxicity are apparent eg. progressive t'oss of weight or inhibition 
of growth. 
6. AUTOPSY 
.All animals surv1v1ng to the end of the study and all animals dying during 
the period of observation should be subjected to autopsy. If in the latter 
cases autolysis is advanced this should be reported. 
7. PRESENTATION OF DATA 
The results from which any calculations have been made should be given in 
detail; the methods of calculat'ion used should be stated. 
The toxic effects should be described ~n each speci~s and for each route 
of administration at'alt dose levels. 
The investigator should draw all relevant conclusions from the data 
obtained in these studies. 
',, ~·. 
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ANNEX II: REPEATED DOSE TOXICITY 
--------
--------· 
.Note for ~uidance concerning the application of the Annex of Directive 
75/318/EEC, 2nd part, Chapter, I; B 2, w1t·h a view 1:o the ~ranting of a ' 
marketing authorization for a new drug. 
1 •. INTRODUCTION 
The purpose of these studi~s is to obtain information on the toxicity of 
a product when repeated exposure to this medicinal product is anticipated· 
in order that an assessment may be made of the risk resulting from thera-
peutic administration of the product, taking into account the products 
of biotransformation. 
' The duration of these studies will be determined by the proposed use in 
~ man or by the intended duration of human exposure. The following. peri~ds 
of administration are suggested as a guidance to correlate the d~ration . 
..of the repeated dose toxicity studies ~ith the proposed duration of· human 
exposure to the drug. / 
Proeosed duration of Suggested duration of 
·human treatment repeated dose toxicity studies 
One or several doses ) 
within one day ) 2 weeks 
Repeated doses for up to ) 
7 days ) 4 weeks 
Repeated doses for upto · ) 
30 days )' 3 months 
Repeated dos~s beyond ) 
30 days ) 6 months 
When human exposure is Likely to be Longer,term, for example when frequent 
discontinuous administration results in a total ·period of exposure of one 
month or more in a period of 1 year, or when retention in the body of'a 
single dose of the drug is prolonged, then the duration of.the repeated 
dose toxicity studies will be ~ix months. 
When it is n~cessary to conduct toxicity studies of three or six months 
duration, a subacute toxicity study of 2 or 4 weeks duration may be 
designed and carried out in such a manner that it acts as a range finding 
study for the Longer term investigation (see 2.5). 
The reason is that administration of too high a dose would Leave too few 
animals alive at the end of the study Lasting three months or more; 
administration of too Low a dose would prevent the development of toxic 
changes. 
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'1.1 General specifications with regard to the repeated dose toxicity 
study 
The introduction of the "Norms and Protocols EC 75/318 Part II, 
Toxicological and Pharmacological Experiments" states that these 
experiments should indica~e inter alia the toxicity thresholds: 
"Repeated dose toxicity tests are intended to reveal any physiological 
and/or pathological changes induced by a repeated administration of 
the active substance,- or combination of active substances under exami-
nation and to determine how these changes are related to dosage. 
Generally it is desirable that two tests be performed: one short-term, 
lasting two to four weeks, the other long-term. The duration of the 
latter shall depend on the conditions of clinical use. Its purpose 
shall be to determine by experiment the non-toxic dose range of the 
product". 
As these thresholds can only be determined when they have been crossed 
the repeated dose toxicity study must be conceived in such a way as to 
demonstrate signs of toxicity. This implies that: 
1.1.1 In the selection of species for long-term studies prior to 
marketing, it is desirable that with regard to the metabolism 
and the pharmacokinetics of the drug the species should be as 
closely similar to man as is possible within the usual spectrum 
of laboratory animals used for repeated dose studies. If there 
are significant differences in metabolism these should be taken 
into account in evaluating the results. 
1.1.2 It is desirable that the pharmacological target organs and the 
pharmacological effects of the product in the species used should 
be the same as those involved in the therapeutic effect 
envisaged for man where this is known and is practical. 
1.1.3 The dosage, the route and the frequency of administration should 
be planned so as to promote a loading of the animal organism 
with the product and its metabolites.sufficient to demonstrate 
the target organ(s) in terms of harmful secondary effects. In 
designing the protocol account will be taken of the pharma-
cokinetics of the drug. 
By continuous administration of a drug in sufficiently high 
doses the following principal stages may be reached: 
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a. The Load of th~ drug in the organism builds up until a 
steady state is reached. 
' b. Adaptation of the organism to the Load with regard to ~he 
pharmacological target organs or the biotransformation 
enzymes or the excretory mechanisms. 
c. In some cases a second metabolic pathway may be activated 
due to an overloading of the primary detoxication pathway; 
as a result a new toxic metabolite may be formed. 
d. A phase of manifestation of target organ toxicity manifested 
by failure of physiological functions and ultimately by 
pathological changes; 
Administration·of the product in the repeated dose toxicity studies 
should be sufficient with regard to dosage and duration to reach this 
final stage d. so that the type of toxicity produced by an excessive 
dose.and the multiple of the therapeutic dose producing toxicity may 
be assessed. Not all drugs can be practically administered in dosages 
that produce target organ toxicit~. Under such circumstances evidence 
shoul~ be produced that the highest possible dose has been given and 
that the drug has been systemically absorbed. 
2. SPECIFICATIONS WITH REGARD TO THE DRUG AND ITS ADMINISTRATION 
2.1 Drug guality 
The active substance should present the same pattern of impurities 
as the product to be marketed, when possible.Should drug substance in 
the final dosage form be shown to have impurities significantly differ-
ent either in quantity or quality from those in the test batch then 
further steps should be taken to ascertain their possible toxicity. 
When the drug is given orally its physical characteristics such as 
particle size may be important; therefore the physical characteristics 
and stability of the material used in the repeated dose toxicity 
studies should be stated in each case.Whenever more than one batch of 
active substance is used in repeated dose toxicity studies this must 
be stated and each batch identified. The batch or batches used in the 
repeated dose toxicity studies should not be of a higher degree of 
purity than those intended for the final product. When the drug is 
given in the diet or the drinking water it should be established 
that it is stable in that medium. 
When a new excipient is used for the first time, it should be tested 
in accordance wi~h the same ~riteria as a new activ~ substance. 
'' 
'·' .,. 
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2.2 Duration of administratibn 
The duration ~f these studies should be related to the duration of the 
proposed therapeutic use in man (see § 1). \ · 
, 2.3 Route of administration 
Whenever this is technically f~asible, the product should be ad-
ministered by the route intended for use in man and it is desirable 
that the pharmacological effect is demonstrable by this route. When 
this cannot' be shown, the use of other routes should be considered. 
(Administration by inhalation i.s discuss.ed in the Appendix). 
The quantity of drug absorbed from the proposed site of administration 
I 
should be known from pharmacokinetic studies. When the product is 
administered in the food or the drinking water, the applicant ~us! 
give assurance that a reasonable and known amount of the drug ingested 
is absorbed. Dosing by incorporation of the test substance· in the 
diet or drinking water requires regular adjustment of the amount of 
drug in the diet or drinking water to compensate for growth and 
changing consumption. 
In addition to systemjc toxicity the possibility of local toxicity 
at the site of application should be given due attention, for example 
in the case of application to the skin, intravaginal application, 
intravenous, intramuscular, rectal, subcutaneous, intra-articular, ' 
intrathecal, conjunctival, intranasal and aural application, or when 
the drug is given by inhalation. 
2.4 Frequency of administration · 
The steady state of the loading of the organism with some pr~ducts 
is reached only when they are administered for seven days a week. 
Usually the administration of a drug to animals should be conducted 
on this basis. If this is not possible the reason should be given. 
When the rate of elimination is slow less fr~quent administration 
may be- acceptable. A rapid rate of elimination or gastric intolerance 
may make it necessary to administer the products more than once a day. 
2.5 Dose levels 
The treatment should include: 
a. A high dose, ~elected for the purpose of causing target organ 
toxicity whenev~r possible or failing this other non-specific 
toxicity, or until limited by volume of dose. 
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For a toxicity study of three or six months duration this dose 
should be derived from a subacute toxicity test of 2 or 4 weeks 
duration, designed ,and carried out as a dose range finding study. 
' 
b. A low dose, suffici~nt to produce a pha~macodynamic effect or the 
. . 
desired therapeutic effect, or to produce blood levels comparable 
to those expected to produce these effects in man. 
c. An intermediate dose, such as the geomet~ic mean between the high 
' 
dose and the low one. 
d. The study should include appropriate control group(s);in'special 
cases a positive control group may be necessary. 
However, the above considerations do not apply when the pharmacodynamic 
effect by itself wilL cause toxicity;. hypoglycaemia by antidiabetic 
agents serves as an example. 
The investigator should indicate the rationale on which the dose 
Levels were selected. 
2.6 Pro.-drugs 
When the product administered is a pro-drug, its conversion to an 
active drug should be demonstrated in the sp~cies under study. 
3. SPECIFICATIONS PERTAINING TO THE EXPERIMENTAL ANIMAL 
3.1 Antmal species: choice and characterisations 
As far as possible the specie? should be chosen on the basis of their 
similarity to man with regard to the pharmacokinetics including the 
biotransformation of the product (see § 1.1.1). 
The pharmacodynamic effect of the drug should if possible be demonstra-
ted in at Least one of the species, so as to provide information 
about the margin between therapeutic and toxic effects. 
The investigator should justify the choice of the species and strain •. 
Use of SPF animals usually increases the value of the study. 
3.2 Sexes 
Normally equal numbers of male and female animals should be used. 
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3.3 Size of Treatment groups 
When the size of the treatment groups is being considered, attention 
should be given to the following: 
a. The size of the treatment groups should be such that all toxi-
cologically important effects due to treatment will be revealed. 
b. The size of the treatment groups should be large enough to permit 
.the sacrifice of animals at intervals before the end of the study 
without interfering with the final.~tatistical ~nalysis. 
' c. The size of the treatment groups should be large enough to allow 
some animals to be retained at the completion of the period of 
dosing so that the reversibility of toxic changes at the end of 
the treatment may be evaluated. 
d. Background knowledge concerning the ranges of variables to be 
studied in the species and strains used is also relevant to 
consideration of group size. 
However, the size of control and treatment groups will always be 
limited for practical and financial reasons and for humane 
considerations. 
3.4 Number of species 
The purpose of the repeated dose toxi~ity studies ii to provide an 
animal model for the repeated administration of the product to man. 
The value of the model for extrapolation to man depends to a large 
extent on the qualitative similarity between the animal model and 
man; this is usually unknown. To reduce the risk of error in extra-
polation, due to effects or lack of effects, which are peculiar to 
one species, at least two species should be used, one being a non 
rodent. The choice of species should be justified (see & 1.1.1.). 
4. ANIMAL HUSBANDRY 
A high level of animal husbandry is required and the environmental 
conditions should be controlled and the diet should be of known constant 
~ 
composition throughout. Measures taken to obtain these conditions should 
be recorded in the report. 
5 .• OBSERVATIONS 
I 
l 
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5.1 /Pretreatment and Control Values 
·1' 
Control data from the•colony are necessary for small mammals for all 
morphological, biochemical and physiological variables. In the case 
of Larger animals pretreatment values should be obtained from the 
animals used in the study. 
5.2 Monitoring during the stud~ 
5.2.1 General monitoring 
General monitoring should be carried out during the study and 
should include food intake, body weight, haematology, clinical 
chemistry, urinanalysis, ophthalmology, ECG and generar behav-
ior. The selection of techniques used and the choice of other 
tests should be appropriate to the current state of knowledge 
and to the animal species being used. In rodents if ECG and 
ophthalmological or other specialised examinations are required 
it is ac~eptable that these are conducted in a limited number 
of animals at each dose level. 
5.2.2 Frequency of monitoring 
The frequency of monitoring in addition to pre-treatment studies 
and final monitoring should be adapted to the manifestations of 
toxicity and also to the pharmacokinetics of the drug. 
The t~sts performed <including the collection of blood samples) 
during the monitori~g should also be performed on the controls, 
and should not affect the experimental animals in a way which 
would influence the final interpretation of the toxicity test 
results. 
5.2.3 Food intake 
When products are administered in the food, particular attention 
should be given to the effect of the product on food consumption. 
Allowance should be made for consequent effects on drug intake. 
5.3 Terminal monitoring 
Terminal observations should be as complete as possible. Autopsy must 
be conducted on all animals. Histopathology should be performed on all 
organs and tissues of the high dose and the control groups Listed in 
the table. In rodents the examination of the Lower dosed groups may be 
.. 
- 45 -
restricted to those organs and tissues showing pathological changes 
at autopsy. In oth~r species where small numbers of animals are used 
histopathology on those tissues listed should be conducted in all 
animals at all doses. 
If organs are not examined microscopically wax blocks or slides should 
be prepared and conserved for five years from the date of marketing 
for examination if required. Peculiarities in the distribution of the 
drug may necessitate further histopathological studies. 
6. IMMUNO-INTERFERENCE 
The expansive growth of immunology and the recognition of its impnrtance 
has made it necessary to pay attention to interference with the immuno-
.. ' .. 
logic system by drugs even ·when this does not belong to their intended 
activity. Such an interference may cause undesired side effects 
<interference with infection; carcinoma). Therefore it is particularly 
important to examine the spleen, the thymus and some lymph nodes macros-
copically and microscopically at t~e terminatiori of the·texicity study. 
These should indicate any e-ffect on the immur:~e system and thus the need 
for further tests. 
Since our present knowledge in this field is rapidly increasing, any 
test used to investigate ~he·immunological effects of a drug should rely 
on the state of the scientific knowledge at that moment. 
7. CONCLUSIONS 
Conclusions should be drawn from these studies.by the investigator. 
. '• 
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APPENDIX A 
List of tissues to be studi~d histologically in a repeated dose toxicity· study 
-gross Lesions 
- tissue masses or tumors <including regional lymph nodes) 
- blood smears. (in case of anaemia, enlarged thymus, lymphadenopathy) 
- lymph nodes 
- mammary glands 
- salivary glands 
- sternebrae, femur or vertebrae (including bone marrow) 
- pituitary 
- thymus 
-·trachea 
lungs 
- heart 
thyroid 
- oesophagus 
- stomach 
- small intestine (Swiss roll method) 
- colon 
- liver 
- gallb-Ladder 
- pancreas 
- spleen 
- kidneys 
- adrenals 
bladder 
- prostate 
- testes 
- ovaries 
- uterus 
- brain (coronal sections at three levels) 
- eyes 
spinal cord 
I, " 
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APPENDIX B 
. Conduct of toxicity studies by inhalation 
1. INTRODUCTION 
Medicinal products intended for administration to humans by fnhalation 
may either be aerosols containing the pharmacologically active substance 
in solid or liquid state or they may be vapors or gases. The Latter 
mentioned products are used as inhalation anaesthetics while aerosols in 
general contain a drug material in the form of particles delivered in a 
propellant which in principle ought to be biologically inactive. 
To~icological studies conducted by inhalation are necessary where: 
(a) Pharmacokinetics after administration by inhalation may differ 
qualitatively or quantitatively from th·e pattern after other routes 
of administration; 
or 
(b) Drug and propellant may interact in the body; 
or 
(c) The inhaled product may have a Local effect in the airways, either 
a short term effect (effect on ciliary function or other signs of 
local irritatton) or a long term effect (emphysema, bronchitis, 
malignancy). 
Aerosols are used for the administration of drugs either (i) to obtain a 
local effect in the respiratory system, or Cii) for the purpose of obtai-
ning systemic effects by using the lining of the airways for absorption 
of the active compound or Ciii) for circumventing the alteration of drugs 
in the gastrointestinal tract. 
In some circumstances toxicological studies on the drug may have been 
performed using other routes of administration, therefore extensive 
toxicological investigation by other routes of administration may already 
have been performed when inhalationaL studies a~ planned. In other cases 
for example, locally acting compounds, such as mucolytic agents, toxi- ' 
cological investigation by other routes of administration may be non-
existant or of little relevance. Plann~ng of the toxicology studies by 
inhalation should take into consideration any already existing toxicologic~l 
or pharmacological knowledge of the substance. 
2. PHYSICO-CHEMICAL PROPERTIES 
The information on the active substance's physico-chemical properties 
should be provided in the same way as for any other toxicological study. 
Additional information should· be provided on the characteristics of the 
aerosol, which should include the distribution of the particle or droplet 
size of the active substance and the physico-chemical specification of 
the substance or substances used as the propellant. 
The propellant system used in these studies should be that proposed for 
the final product. If a novel propellant system is used, this should 
itself be investigated to the sam~ standard as a new active substance. 
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3. DOSING SCHEDULES 
3.1 Administration 
The method of administration depends on the nature of the substance 
and the intended use in ·man. In acute studies it may be reasonable 
to administer the substance directly into the airways via a naso-
tracheal tube or through a tracheotomy. In this way the quantity 
administered can be determined directly. 
In the case of Long term exposure studies it will usually be necessary 
to use either "head only'~ or "nose only" exposure chambers or masks 
for inhalation. If whole body exposure is used deposition of the drug 
on the skin, in the pelt, in the upper airways and the amount 
swallowed should be taken into account in determining the dose of 
substance administered. 
It should be demonstrated· that the method of administration ensures 
that the substance reaches the desired site. 
3.2 Dose Levels 
In these studies normally three dose Levels and one or more control 
groups as appropriate should be used in both single dose and repeated 
dose studies. Different Levels of drug exposure can be achieved by 
alteration of concentration of substance inhaled or by alteration of 
the duration of exposure. In the selection of dose Levels the same 
principles should apply, as far as is possible to those used for 
toxicity studies by other routes. 
The reasons for selecting particular dose Levels should be given. 
3.3 Duration of Study 
The duration of the study should be related, at Least to some extent, 
to the proposed human exposure. 
4. PHARMACOKINETICS AND METABOLISM 
The metabolic pattern of the drug administered by inhalation may differ 
from the pattern observed foltowing other routes of administration. 
The investigator should determine whether there are any pharmacokinetic 
or metabolic differences of relevance for the interpretation of the 
toxicological studies conducted by the inhalational route. 
/When biotransformation occurs in the Lung itself the possibility of 
enzyme induction of this process should be taken into consideration.7 
5. ANIMALS 
The experimental animals used in these studies should be free of pulmonary 
infection and have~ low incidence of,other pulmonary pathology. 
The number of experimental animals to be used in each group should be 
adequate for statistical analysis and will be determined by the duration 
of the experiment and by the number of observations, measurements and 
interim sacrifices to be made during the exposure periods. At least one 
rodent and one non-rodent species should b~ used for all repeated exposure 
studies. · 
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6. OBSERVATIONS 
Interim monitoring and terminal studies should be conducted as indicated 
for other toxicitx studies. Particular attention should be paid to any 
local effects. If the drug is to be administered repeatedly special 
studies of ciliary function and on the microflora may be necessary. 
Blood Level monitoring of drug and propellant·or other methods of 
assessing ·absorption of drug and propellant should be performed at 
intervals during repeated dose studies. 
Terminal examination 
At the conclusion of the study all animals should be· subjected to autopsy 
and examination of tissues should be conducted as with other toxicological 
studies. 
In studies conducted by the inhalational route the Lungs should be 
weighed in all ani"mals and histopathological examination conducted on 
tissues taken from all exposed Levels of the respiratory tract and from 
associated Lymphoid tissue • 
. 7. PRESENTATION OF RESULTS AND CONCLUSIONS 
These should be drawn up in ihe same manner as in other toxicity studies 
and the investigator should draw appropriate conclusi9ns from the study. 
' 
I) 
i." 1 I 
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· ANNEX III: REPRODUCTION STUDIES 
========== 
Note for Guidance concerning the application of the Annex of Directive 
75/318/CEE, 2nd part, Chapter ·I, C and D, with a view to the granting of 
a marketing author1~ation for a new drug. 
11ENERAL s·TATEMENT 
The study of drug .effects on reproduction should be conducted on all new 
/ . drugs in such a manner as would reveal the presence of any effect on 
m·ating behaviour and of any effect which might result in fetal Loss, fetal 
abnormality and damage to the offspring·in Later Life, eg, 
(i) changes in fertility or in the production of abnormal young due 
to damage to the m~Le and/er female gametes, 
(i i) interference. with preimplantation and implantation stages in 
the development of the conceptus, 
( i i i) toxic effects on the embryo,. 
( iv) toxic effects on the fetus, 
(v) changes in maternal physiology producing secondary effects on 
embryo or fetus, 
(vi) effects on uterine or placental growth or development, 
(vii) interference with parturition, 
(viii) effects on postnatal development and suckling of the·progeny, 
and on maternal lactation, 
Cix) Late effects on the progeny. 
SPECIFIC GUIDELINES 
In the interpretation of the following notes for guidance it must be 
appreciated that they are not rigid requirements and may not be universally 
applicable. Interpretation should therefore be flexible and related to 
. the propos~d use of the drug; justification for ~hoice of studies must be 
given. 
1. SELECTION OF SPECIES 
Embryotoxicity studies should normally be conducted on two mammalian 
species one of which should be other than a rodent. Fertility and 
perinatal studies should be conducted in at Least one species. 
Where metabolism of a drug in a particular species is known to be 
similar to that in m~n, it is desirable to include this species. 
It is desirable that one,of the s~ecies is the same as in the Long 
term toxicity studies. Studies in a third species may be helpful if 
conflicting results are obtained in the initial two species. The 
species and strains used in ~he studies should be specified. 
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2. DOSAGE 
Dosing should no~mally be conducted at three dose levels. 
The high dose usually should be such that eviden~e of some maternal 
toxicity is produced,for example decrease in body weight gain. The 
low dose should be sufficient to produce a pharmacodynamic effect 
similar to the desired therapeutic effect, or to produce blood levels 
comparable to those required ~9 produce the effect (this does ~ot apply 
if the pharmacodynamic effect by itself will cause toxicity). The 
intermediate dose should be the geometric mean of the high and low doses. 
Dosing should be conducted by the proposed route or routes of clinical 
administration. 
Dosing schedules for investigation of drug effects on reproduction should 
normally include 
(a) embryotoxicity studies; dosing throughout the period of embryogenesis 
(organogenesis) in two species one of which should be other than a 
rodent, 
(b) a fertitity study should be conducted in at least one species. 
Dosing should commence in male and female animals at a sufficient 
time before the proposed mating so that any effects of the drug o~ 
gametogenesis could be revealed. Dosed animals may be mated with 
dosed partners but in the event of positive findings of a reproductive 
defect then the study should be repeated using dosed animals mated 
with undosed partn~rs. After mating the dosed females should continue 
to be dosed throughout pregnancy. 
Half the females should be killed during gestation, preferably 
some days before the expected date of parturition, and the fetuses 
removed by Caesar~an Section and examined. The remainder of the 
females should be allowed to litter normally and rear their progeny. 
(c) Perinatal studies should be conducted in at least one species. Dosing 
should cover the period of gestation from the end of organogenesis to 
parturition and should extend throughout the per1od of lactation up to 
weaning. 
3. NUMBERS OF ANIMALS 
An adequate number of animals should be used ~t each dose level to enable 
valid assessments to be made. With the exception of primates, the 
following minimum numbers per dose level are suggested: 
(a) Embryotoxicity studies: 20 pregnant females in rodents, 
12 pregnant females in non-rodents; 
(b) Fertility studies: 24 females and 24 males; 
(c) Perinatal studies: 12 pregnant females. 
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Where a third species is used it is suggested that adequate numbers 
of dosed animals should be used together with controls to allow a clear 
conclusion to be drawn fr'om the study. 
4. HOUSING AND DIET 
Full details of the housing and caging conditions of the animals must 
be given. The full specification of the diet (including additives) 
must be provided. 
5. PHARMACOKINETICS 
In the conduct of reproduction ~tudies account should be taken of the 
pharmacokinetics of the drug in the pregnant animal~ The Level of 
exposure of the fetus to the drug should have been determined as far 
as this is technically possible. 
6. EVALUATIONS 
(a) Examinations should be made of the fetuses from the animals dosed 
during the period of embryogenesis. Animals should be killed and the 
fetuses removed by Caesarean Section. In these animals the numbers 
of corpora Lutea, implantation sites <visible and those determined 
by special techniques e.g. by'the Salewsky method), resorptions, 
the weight and sex of their individual fetuses should be recorded. 
The individual fetuses should be examined for external abnormalities 
and adequate examination of the skeleton or viscera or both made on 
all fetuses. Where obvious abnormalities are found further appropriate 
examination should be conduct~d. Special attention should be paid to 
abnormally high numbers of resorptions as this might indicate the 
need for further studies for teratogenic effects in the-early stages 
of pregnancy. 
(b) In the fertility study females killed during the period of gestation 
should have their fetuses delivered by Caesarean Section and the 
following information should be recorded: number of corpora Lutea, 
implantation sites, resorptions, weight and sex of individual 
fetuses. ALL individual fetuses should be examined for either skeletal 
and/or visceral abnormalities. 
From animals dosed during the fertility study and allowed to Litter 
normally and rear their progeny to the stage of weaning, a Large 
enough number of progeny to allow for the subsequent investigations 
should be allowed to Live and reach maturity. Late effects of the 
drug on the progeny in terms of auditory, visual and behavioural 
impairment should be assessed. Reprcductive function should be 
determined in the progeny by allowing at Least one male and one 
female from each Litter of dosed animals to breed and produce one Litter 
(brother/sister mating is not ~nvisaged). 
(c) The females dosed through tbe pre- and-post-natal period should be 
allowed to litter spontaneously and the progeny examined at weaning. 
ALL animals killed at the end of Lactation should be subjected to 
a thorough autopsy examination. Under certain circumstances 
,. 
.·., 
'. 
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some of the progeny may be allowed to Live and reach maturity so 
that their reproductive capacity could be assessed, and other 
Late effects of the drug on the progeny in terms of behavioural, 
visual and auditory impairment determined. 
7. CONCLUSIONS 
The investigator is required to draw overall conclusions from the results 
of these studies indicating either 
(a) there is no evidence of adverse effects of the drug on reproductive 
function, ·or 
(b) there is evidence of adverse effects on reproductive function(s) 
to be specified, 
or 
(c) the data are inadequate to draw conclusions. 
If particular studies have been omitted the investigator should justify 
the omissi·on. 
APPENDIX 
Duration of gamet~genesis. 
In rodent studies dosing of the male should be for a m1n1mum of 60 days 
and the female for a minimum of 14 d~ys prior to mating. Animals should 
be about 40 days of age at the commencement of dosing. In the present 
stage of knowledge these times would be regarded as acceptable. 
. I 
... 
ANNEX IV~· CARCINciGENICITY - 54-
N~t~==f9~ Guidance conterni~g the application of the Annex of .Directive 
75/318/EEC, 2hd part, Chapter I, E,:with.a view to the granting of a 
marketing authoriza~ion for a new drug. 
' ' 
The strongest evidence·that a compound is a carcinogenic hazard for man is 
, epidemiological although most known human carcinogens are found to be 
carcjnogenic for e~perimental animals'. There is no evidence that all substan-
ces which are carcinogenic for animals are also carcinogenic for man, but 
it is difficult to declare any compound as being non-carcinogenic for man 
when it has been shown to be carcinogenic in animal studies. 
,/ 
Extrapolation to man is a difficult, ~ometimes arbitrary, procedure, and the 
ideal would be to an~Lyse the mechanisms involved in increasing the incidence 
of the experimental tumours and to determine whether such mechanisms invol-
ving specific biochem~cal pathways and the formation of the proximate carci-
nogen would be applicable to ma~. The criteria on which extrapolation is. 
based may vary with the agent under consideration, it~ projected use, dosage 
and mode of administration on the one hand, and the species, sites, incidence 
of tumours ·and required test dosage, on the other. 
The Likelihood of carcinogenic risk in man is iricreased if there is a high 
yield of malignant tumours involving a specific tissue when the test animal 
is given the test substance by the route to be used in man and at a dosage 
~qual.to or Cower than that which induces minimal toxicity. However, since 
there is no good evidence of a threshold Level, an inerease in yield of • 
benign tumours, or malignant tumours at higher dosage, or reduction of 
Latency should be interpreted as constituting a possible risk for. man. In 
such circumstances the agent is generally regarded as Less potent and the 
risk may more easily be reconciled with benefits associated with the thera-
peutic use of the compound. 
/ 
t. REQUtREMENTS F0R CARCINOGENICITY STUDIES 
- Carcinogenicity studies will usually be required in the following 
circumstances: 
(a) When the medicine is Likely to be administered regularly over a 
substantial period of Life (continuously during a minimum period of 
6 months, or frequently in an intermittent manner so that the total 
exposure is similar). · 
or (b) Where a substance has a chemical structure that suggests a ~arcino­
genic potential 
or (c) Wh~re a substance causes concern due to 
(i) Some specific aspects of its biological action (eg a 
therapeutic class of which several members have produced 
positive carcinogenic results). 
(ii) Its pattern of toxi~ity or Long term retention (of drug or 
metabolites) detected in previous st~dies. 
(iii) The findings in mutagenicity tests and/or short term 
carcinogenicity tests. 
'\', .;. 
. I 
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Carcinogenicity testing may not be regarded as necessary where the 
substance in question will be used only in p_atients ·with a life· 
expectancy shorter than that in which a_ chemical might reveal any 
carcinogenic hazard in man. If circumstances alter and a drug of 
the latter variety were used in less seriou~ conditions then 
carcinogenicity testing would become necessary. Insoluble substances 
which are not absorbed may not' require formal carcinogenicity studies. 
2. SPECIES AND STRAIN SELECTION 
Where carcinogenicity studies are required they should normally be 
conducted on two species. Th~ metabolic handling of the drug should be 
known in the species used and should preferably show similarities to the 
metabolism in man. Cognisance should be taken of known species and strain 
responses with similar chemicals. Species and strains with a high inci-
dence of spontaneous tumour formation should normally be avoided. Those 
undertaking the study should select species and strains known to be 
sensitive to one or more carcinogens. Positive controls will not be 
required routinely but the spontaneous tumour incidence of the strains 
used should be recorded. · 
3. DOSAGE 
(a) Route and frequency of dosing 
Where possible, dosing should be conducted by the proposed clinical 
route of administration. Where relevant, evidence of absorption 
should b~ provided. The frequency of dosing normally will be daily. 
(b) Dose levels 
Carcinogenicity testing should normally be conducted at 3 dose levels. 
The top dose should produce a minimum toxic effect, for example a 
10% weight loss or failure of growth, or minimal target organ 
toxicity. Target organ toxicity will be demonstrated by failure of 
physiological functions and ultimately by pathological changes. The 
lowest dose should be of the order of 2-3 times the maximum human 
therapeutic dose or the dose that produces a pharmacological effect 
in animals. The middle dose should be the geometric mean of the high 
and low dose. 
Exceptions to these principles may occur, for example where the toxic 
dose of the drug is a high multiple of the therapeutic dose; in these 
circumstances it is acceptable if the top dose is set at approximately 
100 times the human therapeutic dose, where technically feasible. 
4. PRACTICAL FEATURES 
J 
Animals should be in good general health initially and this should be 
maintained throughout the study. High standards of animal husbandry are 
essential. Special precaution~ are necessary when inhalational or volatile 
carcinogens are being tested. 
The pharmaceutical quality of the batch(es) used should be clearly 
characterised. 
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(a) Ag~ of animals at commencement of study 
Carcinogenicity studi~s should commence as soon as possible after 
,weaning i.e. as soon as the animals are accustomed to their diet 
and surroundings. 
(b) Duration of studies 
The currently recommended practice is to conduct studies f.or 24 months 
in rat and 18 months in the mouse and hamster. Where the survival 
rate is high there may be advantages in extending studies for 30 
months in the rat and 24 months in the mouse or for the l ifespan of 
the animals i.e. to 20 % survival in the controls. , 
(c) Number of animals per group 
For routine tests with mice, rats and hamsters it is suggested that 
for· each sex there should be 50 animals per treated group, and, two 
control groups of 50 for each sex dosed with the venicle by the same 
route (in most cases the drug will be administered in the diet). 
(d) Composition of diet 
Commercial dieti are variable and steps should be taken to provide 
as uniform a diet as possible throughout the dur~tion of the 
carcinogenicity study. Full specification of the diet should be 
given. 
5. ADDITIONAL MONITORING 
Carcinogenicity studies should be designed to obtain the maximum amount 
of information from the animals used but any investigations undertaken 
to elicit additional toxicological data should not prejudice the prime 
purpose of evaluating a drug's carcinogenic potential. Information on 
absorption, distribution and metabolism of the drug and on whether th~ 
drug accumulated or was an enzyme inducer should have been determined 
during other toxicity studies. 
6~ STATISTICAL DESIGN OF STUDY 
An appropriate experimental design should be selected and in particular: 
(i) The cages containing the animals in the treatment and control 
groups ~hould be distributed within the animal house so as to 
eliminate bias due to the effects of any local environmental 
factor. 
(ii) Animals should be allocated at random to the various experimental 
units (e.g. cages) and the method used to achieve this randomisation 
should be clearly stated. 
(1ii) If for practical reasons of handling such large numbers of animals 
it is decided to stagger the start of the study it is desirable that 
all groups should be represented at each start in equal numbers. 
If the study is conducted using a staggered start the times at 
which the various batches of ~nimals enter the study must be stated. 
' .r 
\' 
I , 
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7. TERMINAL INVESTIGATIONS 
7.1 Autopsy 
A full autopsy should be made on all animal3 dying during the study 
or killed because of their poor condition. 
At the conclusion of the study all surviving animals should be 
sacrificed and a full ~utopsy conducted on each' an~mal. Previbusly 
demonstrated toxic effects may indicate particular topics for 
investigation. Haematological and biochemical investigations may be 
helpful in the interpretation of any Lesions found. 
7.2 Histopathology, 
7.2.1 Carcinogenicity s~reening: 
(i) Microscopical examination should be carried out on all 
Listed tissues and organs from all high dose animals and 
from all controls 
and 
Cii) tissues from any animal in any group in which macroscopical 
Lesions of any kind are found at autopsy; 
If the results from (i) indicate that tumours occur in one 
or more organs or tissues, then 
(iii) those• tissues and organs should be examined in the mid-
and Low-dose groups even when macroscopically normal. 
ALL Listed tissues should be microscopically examined from 
all animals dying or killed during the course of the 
study. , 
7.2.2 Toxicity screening: 
Previously demonstrated toxic effects may indicate parti-
cular aspects for investigation. 
Haematological and biochemical investigations may be 
helpful in the interpretation ~f any L~sion found. 
Particular attention should be paid to the site of 
application if the drug is administered other than by 
the oral route~ 
&. PRINCIPLES OF REPORTING ON CARCINOGENICITY STUDIES 
8.1 Definitions , 
A neoplasm (tumou~) is regarded as a population of abnormal cells 
with uncontrolled and usually increased proliferative activity and 
other Less well-defined morphological and functional features. 
A malignant neoplasm is one which invades surrounding tissues or 
metastasises. In general terms, the tumour is considered to ,be 
benign or malignant on the basis of its histopathological appearances 
and the correlation by the pathologist of such cha~ges with 
. I. ,,. 1'.'' 
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biological behaviour known from·p~evious experience to occur in 
tumours displaying comparable charact.eri sti cs. 
Tumours should. be described in conventional histopathological terms 
according to. ~ell ... def,1ned• classi..fi ce~ions (e.g. W.H.o.'). 
8.2 Presentation of the data 
In the first instance the findings should Qe summarised for each 
treatment group and each control grou~ separately, keeping the 
sexes separate, in terms of: 
1. Number of. animals examined and their individual gross and 
microscopic examination; 
2. Numbers (and p~rcentages) of animals with·tumours of each identi-
fied type in a specified tissue, distinguishing malignant from 
benign tumours, wherever possible; 
3. For animals with one or more tumours of the same or different type, 
a frequency distribution of the total number of tumours found in 
the animal; and another of the total number of malignant tumours 
found in the animal. If the tumours cannot be enumerated some 
grading of multiplicity of ~umours should be used instead; 
4. Time to each interim deathf 
. 5. Time of appearance of any mass (starting from clinical palpation)· 
and its progress; as well as its eventual histopathology. 
9. ANALYSIS OF THE DATA 
The form of the analysis and the tests of statistical significance used 
should be appropriate to the type of data and to the basic experimental 
design. The statistical procedures used should be clearly stated. · 
The responses should be assessed in the following ways: 
(i) The total incidence of tumour bearing animals. 
Cii) The total incidence of tumours. 
(iii) The incidence of tumours involving a specific tissue. 
(iv) The incidence of tumours judged to be malignant. 
(v) ~e Latent period to tumour appearance (using actuarial 
approaches). 
The analysis should be directed towards: 
(a) the assessment of the presence of any effect of the substance 
under study, as shown by the contrast between the response in 
the 3 treatment groups, as a set,. and the response in the 2 
,control groups, as a set. 
.. 
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(b) the assessment of whether any effect is dose-related, as 
shown by a trend in the responses in the low, middle and high 
dose groups. 'This assessment is statistically independent·of 
that ih (a). 
Professional statistical advice should be available in order to assess 
the influence of other factors, such as death of test animals because 
of other diseases, and premature killing of animals because of clinical 
detection of tumours. The particular tests of statistical significance 
which should be used in assessing the presence of an effect or a dose-
relationship are intentionally not specified. The data in one 
experiment may require a different approach from the data in another. 
I 
The test substance should be regarded as having the potential to increase 
the risk of neoplastic change if any of the above resp~nses is materially 
increased Cor the latent period is materially decreased). The compound may 
be regarded as possessing more powerful activity for the animal if several 
of the above responses are affected and if there is evidence of a dose-
response as well as the presence of the effect. A raised incidence of 
tumours in treated as compared with control animals is of significance 
whatever the mechanism postulated or defined for the development of s~ch 
tumours, but any particular circumstances should be identified or remarked. 
Examples include known pathways which may be peculiar to one species 
(griseofulvin and porphyrin metabolism in the mouse), severe stimulation 
of endocrine glands (especially in the dog), or the development of 
physical features peculiar only to the test species (vesical calculi in 
the rat). 
Different circumstances ~ay result in: 
\ (i) an increased incidence or reduced latency of malignant tumours 
(ii) an increased incidence of benign tumours 
(iii) local induction of tumours at the site of injection. 
10. USE OF SHORT-TERM CARCINOGENICITY STUDIES 
Evaluation of new compounds in a mutagenicity screen is desirable. 
H6wever, available techniques involving s~ort-term testing of chemicals 
for mutagenicity/carcinogenicity are not capable of replacing formal 
carcinogenicity testing in animals as a means of evaluating a drug's 
carcinogenic poteritial. Short-term studies giving positive results will 
always indicate the need for formal carcinogenicity studies if the drug 
is to be developed further; those giving negative results do not preclude 
the need for formal studies when these are advisable for the reasons given 
in paragraph 1 above. 
11. CONCLUSIONS 
Conclusions from these studies should be drawn by the investigator. 
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APPENDIX 
List of tissues to be studied, histologically in a carcinogenicity study 
- gross Lesions 
- tissue masses or turners (including regional Lymph nodes) 
- blood smears (in case of anaemia, enlarged thymus, Lymphadenopathy) 
- Lymph nodes 
- mammary glands 
- salivary glands 
- sternebrae, femur or vertebrae ( including bone marrow) 
- pituitary 
- thymus 
- trachea 
- Lungs 
- heart 
- thyroid 
- oesophagus 
- stomach 
- small intestine (Swiss roll method) 
- colon 
- liver 
- gallbladder 
- pancreas 
- spleen 
- kidneys 
- adrenals 
- bladder 
- prostate 
- testes 
- ovaries 
- uterus 
- brain (coronal sections at three Levels) 
- eyes 
- spinal cord 
' ; 
' 
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ANNEX V: PHARMACOKINETICS AND METABOLIC STUDIES IN THE SAFETY EVALUATION 
======== OF NEW DRUGS IN-ANIMAlS 
Note for Guidance concerning t~e application of the Annex of Directive 
75/318/EEC, 2nd part, Chapter I, F and G, with a view to the granting of 
a
1 
m~rketing authorization for'a new drug. 
1. INTRODUCTION 
These notes are concerned with the time course of the absorption~ 
distribution and excretion of new drugs and with their metabolism in 
relation to their safety. For many steps in the ,evaluation of a drug 
such data are essential, for example: 
(a) to assess the Levels of the drug and of its metabolites 
and their kinetics in blood, body fluids and organs; 
(b) to obtain information on the relationship between target 
organ toxicity and the blood, body fluids and organ 
concentrations of the drug; 
(c) to assess the possibility of enzyme induction~and of 
cumulation of the drug with repeated administration; 
(d) to choose where possible the animal species to be used in 
toxicological studies on the basis of their similarity to 
man in handling the drug, and to dete~mine the relevance 
of these toxitity studies to man. 
2. DRUG SPECIFICATION 
Specification of the physical and chemical properties of the drug 
substance must be given and the stability of the preparation should 
be provided. 
When a Labelled drug is used the position of the Label in the 
molecule and the specific activity of the material must be stated. 
Consideration should be given when selecting the position of the 
Label to its Likely metabolic fate. 
3. METHODS 
Data on the Levels of drug and metabolites in blood, body fluids, 
organs and in the excreta can be obtained by physical, che~ical or 
biological methods. The investigator should justify the details of 
the methods used, their validity and reproducibility, including the 
specificity, precision and accuracy. (The study of the time course 
of its pharmacodynamic effects may provide useful additional 
information). 
When using Labelled drugs attention must be given to the fact that 
the measured Label in body fluids may not correspond to that of the 
unmodified drug, but may include Labelled metabolites and conjugates. 
Attention should be given to the possibility of·isotope exchange 
with endogenous compounds. 
I' 
l 
I 
4. SPECIES 
5. 
The animal species in these studies usually should be those normally 
used in the laboratory for phar.macologi cal. and toxicological 
investigations. The reasons for selection of any other species , 
should be given. 
\ . 
A preliminary study of kinetics- and metabolism of the drug in a few 
human subjects could provide useful information in choosing the 
animal species to be used in repeated dose toxicity studies. 
DRUG ADMINISTRATION. 
Doses and routes of drug administration should be related when 
possible to th~ proposed clinical use of the drug. One of the routes 
selected should ensure the absorption-of the drug if this is relevant 
to human usage. 
' . 
6. PRESENTATION OF RESULTS 
\ 
Information should be presented on the following items: 
(i) 
( i i) 
<i-ii) 
<iv) 
(v) 
(vi) 
<vi i) 
<viii) 
(ix) 
absor6tion (fractional absorption, kinetics); 
distribution in the principal organs and tissues and the 
time courte in body. fluids; 
blood, plasma or serum half life; 
plasma protein binding; 
characterization of the pattern of metabolites in excreta, 
and where practicable, identification of major metabolites; 
route and time course of excretion of drug and metabolites; 
if biliary excretion is a major route of elimination, then 
the possibility of enterohepatic recycling should be 
investigated; 
a quant~tive account of the fate of the administered dose 
should be attempted; 
possibilities of enzyme induction should be investigated. 
If enzyme induction is found its relevance in the context 
of the proposed use of the drug should be examined. 
7. CONCLUSIONS 
Appropriate conclusions should be drawn f~om these studies in· the 
context of the objectives indicated in paragraph 1. 
.!, 
- 63 -
ANNEX VI: FIXED COMBINATION PRODUCTS 
---------
Note for Guidance concerning the application of the Annex of Directive 
75/318/EEC,. 3rd part, Chapter II, c 2, with a vie.}" to the granting of . 
a marketing authorization for a new drug. 
1. JUSTIFICATION 
Applicants will be required to justify the particular combination of 
active ingredients proposed. Fixed combination products will only be 
considered acceptable if the proposed combination is rational and based 
on valid therapeutic principles. ~ 
-
For any individual combination it will be necessary to assess the potential 
advantages in the ~linical situation against possible disadvantages, in 
order to determine whether the product meets the requirements of the Norms 
and Protocols with respect to efficacy and safety. 
Potential advantages of fixed combinations include! 
1. an improvement in the therapeutic/toxic ratio, e.g. as a result of the 
potentiation of the therapeutic effect; 
2. simplification of the~apy, resulting i~ improved patient compliance. 
Disadvantages of fixed combinations include: 
1. the fact that even a combination which meets the need of the average 
patient is unlikely to be ideally formulated for the needs of the in-
dividual; 
2. accumulation of adverse reactions. 
Combinations may not be considered rational if the half-life and/or the 
dur~tion of action of the components differ significantly, but this may 
·not necessarily apply where it can be shown that the combination is 
clinically valid despite differences in this respect e.gw, if one compo-
nent is intended to enhance absorption of the other or where the components 
are intended to exert their effects successively. · 
The inclusion of an ingredient to counteract an adverse effect of one Qf 
the other components may be considered justified but only if the adverse 
reaction is a commonly occurinq one. 
The inclusion of a component intended to produce unpleasant side-effects 
as a means of preventing abuse is undesirable. 
Substances having a critical dosage range or a narrow therapeutic index 
are unlikely to be suitable for inclusion in fixed combinations. 
2. INDICATIONS 
The indications claimed for a fixed combination product should be such 
that each component is needed for each indication. The product should be 
formulated so that the dose and proportion of each component present is 
appropriate to all the recommended uses. 
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Clearly, an "indication" must be a well-recognized disease state, dysfunc-
tional state, syndrome or pathological entity. The individual components 
of a fixed combination may be intended to relieve simultaneously different 
sympto~s of such a disease state, but it will not be proper to regard each 
indjvidual symptom as an indication for the ;fixed, combination, since it may 
also occur in other diseases and for treating this symptom alone the other 
constituents may be irrelevant. 
3. SAFETY AND EFFICACY 
A distinction must be made between those fixed combinations which correspond 
closely to combinations which are already in widespread use provided these 
are thoroughly and reliable documented, and those combinations- which are 
essentially new <either because the drugs involved are not usually combined 
because the quantitative composition is unusual, or because one of the 
components is entirely new). 
Safety studies in animals with fixed combinations should as a general rule 
have been performed with the active ingredients in the proportions present 
in the product. Such studies will not be required where all the components 
have been extensively and safely used in humans in ident1cal or very simi-
lar combinations for a long period ~nd the safety of such combinations is 
well-documented. 
Both the efficacy and the £afety of a fixed combination product should have 
been investigated in man. For well-recognized combinations well-founded 
~ibliographical data will be acceptable in some cases. It will be neces-
sary to test a new combination clinically against one or more of the com-
ponents in order to define the role played by each in the total. 
4. INTERACTIONS 
The possibility of interactions between the components should always be 
considered. Where- a pharmaceutical, pharmacokinetic or pharmacodynamic 
interaction appears possible, the applicant should submit data either to 
establish that such interaction does not occur, or that it is clearly 
recognized and defined. 
5. ADVERSE EFFECTS 
Where there are grounds to expect that a fixed combination product may be 
substantially more harmful or give rise to much more frequent adverse ef-
fects t~an any individual components given alone, the applican~ should 
provide evidence that this does not occur in therapeutic use, or that the 
advantages of the combination, e.g. increased efficacy, outweigh such 
disadvantages. 
6. DOSAGE 
The combination product m~st be safe and effective throughout the whole 
of the recommended dosage range. 
7. COMBINATION PACKS 
The principles applicable to fixed combination products will also be applied 
in the assessment of preparations consisting of different medicinal products 
in combination packs where the f)roducts are intended for simultaneous or 
sequential administration. 
8. CHEMICAL COMBINATIONS AND COMPLEXES 
Substances of this type which dissociate prior to absorption into two or 
more active component~ may be regarded,for the application of the previous 
provisions c% fixed ccmbinations of these substances, rather than as chemi-
cal entities. 
,1' 
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9. LABELLING 
The pres~ntati~n and label.ling of a fixed combination product should be 
such that it is clear to the prescriber or purchaser that the product 
contains more than one active ingredient and the pharmacological nature 
of the active ingredients should be clearly stated in appropriate terms. 
